Study: To be cost-effective, Gilead's new HIV pill needs near-50% price cut

Study: To be cost-effective, Gilead's new HIV pill needs near-50% price cut

STAT Plus: A recently approved Gilead HIV prevention pill is not cost-effective and price should be cut in half, study says

By ED SILVERMAN

RICH PEDRONCELLI/AP

“We agree Descovy has a different, albeit improved safety profile ... but how much more should we be willing to pay?” asked one study author.

READ MORE